Mantis Biotech vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (85 vs 32)
Mantis Biotech logo

Mantis Biotech

EmergingBioTech

AI Clinical Trial Simulation

YC-backed AI company raised $48M Series A co-led by a16z Bio and GV in Feb 2026; builds digital twins of human physiology to generate diverse synthetic clinical trial populations, addressing chronic underrepresentation of women and minorities.

AI VisibilityBeta
Overall Score
D32
Category Rank
#1 of 1
AI Consensus
48%
Trend
up
Per Platform
ChatGPT
23
Perplexity
42
Gemini
27

About

Mantis Biotech is a YC-backed AI company that builds digital twins of human physiology to synthesize diverse, realistic clinical trial populations. The company addresses one of drug development's most persistent problems: clinical trials consistently underrepresent women, elderly patients, and minorities, producing efficacy data that fails to predict real-world outcomes across populations. Mantis's AI platform generates synthetic patient data that fills these representation gaps.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
A85
Category Rank
#1 of 2
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
77
Perplexity
95
Gemini
83

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

32
Overall Score
85
#1
Category Rank
#1
48
AI Consensus
57
up
Trend
up
23
ChatGPT
77
42
Perplexity
95
27
Gemini
83
23
Claude
87
37
Grok
79

Key Details

Category
AI Clinical Trial Simulation
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Mantis Biotech
AI Clinical Trial Simulation
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.